Actelion Ltd. and Lundbeck Inc. Get Positive CHMP Opinions
Published: Oct 28, 2013
The latest set of opinions from advisors to the European Medicines Agency has seen two new medicines recommended for approval. The agency's Committee for Human Medicinal Products (CHMP) has issued a positive recommendation on Opsumit (macitentan), Actelion's new treatment for pulmonary arterial hypertension. The drug, which was approved by the US Food and Drug Administration earlier this month, is the follow-up to the Swiss biotech's blockbuster Tracleer (bosentan), which goes off-patent in 2015.
Help employers find you! Check out all the jobs and post your resume.